Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT04805203 Terminated - Multiple Myeloma Clinical Trials

Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma

Covimmunomm
Start date: December 16, 2020
Phase: N/A
Study type: Interventional

Among all MM patients included in the cohort at the time of diagnosis of SARS-CoV-2 infection, blood samples will be collected at inclusion, at time of the infection acute phase in the most severe cases (when admitted in intensive care units), and at recovery. The following immune function tests will be evaluated, gammaglobulin measurements, lymphocytes counts, B, T, and NK cells analyses by cytometry, including exhaustion analyses. In addition, T cell repertoire sequencing looking for SARS-CoV-2- specific T cells, and serologies, will be evaluated at recovery and 6 months after MM treatment re-initiation.

NCT ID: NCT04776018 Terminated - Clinical trials for Relapsed and/or Refractory Multiple Myeloma (RRMM)

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Start date: April 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM). The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination with anti-CD38 (mAbs) and to determine the recommended Phase 2 dose (RP2D). Participants will be on this combination treatment for 28-day cycles. They will continue with this treatment until disease progression or unacceptable toxicity.

NCT ID: NCT04770402 Terminated - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients

Start date: September 15, 2021
Phase: N/A
Study type: Interventional

This randomized, controlled trial is designed to evaluate the effect of acupuncture on Chemotherapy-Induced Peripheral Neuropathy (CIPN), other symptoms, and potential opioid and concomitant medication sparing effects in comparison to standard of care management in Multiple Myeloma subjects.

NCT ID: NCT04730505 Terminated - Multiple Myeloma Clinical Trials

A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM

MyHOPE™
Start date: February 4, 2021
Phase: Phase 1
Study type: Interventional

NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM. The MyHOPE for MM Platform is a validated investigational device manufactured by Amalgam Rx, Inc. and designed to provide patients with a comprehensive set of tools and resources to support the patient throughout their overall experience with MM.

NCT ID: NCT04700176 Terminated - Multiple Myeloma Clinical Trials

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

Start date: May 2, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and efficacy of the study drug daratumumab, when given together with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA).

NCT ID: NCT04649060 Terminated - Clinical trials for Relapsed Multiple Myeloma

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

LIGHTHOUSE
Start date: December 21, 2020
Phase: Phase 3
Study type: Interventional

This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with Relapsed-Refractory Multiple Myeloma (RRMM) who were either double refractory to an Immunomodulatory Drug (IMiD) and a Proteasome Inhibitor (PI) (regardless of the number of prior lines of therapy), or had received at least 3 prior lines of therapy including an IMiD and a PI. Patients received treatment with melflufen+dexamethasone+daratumumab or daratumumab until documented progressive disease, unacceptable toxicity, or patient/treating physician decision. Patients in the daratumumab treatment arm had the option to receive treatment with melflufen+dexamethasone+daratumumab after confirmed progressive disease.

NCT ID: NCT04635735 Terminated - Clinical trials for Relapsed/Refractory Multiple Myeloma

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Start date: January 12, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone.

NCT ID: NCT04614636 Terminated - Multiple Myeloma Clinical Trials

FT538 in Subjects With Advanced Hematologic Malignancies

Start date: October 17, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

NCT ID: NCT04521335 Terminated - Multiple Myeloma Clinical Trials

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

Repurpose-1
Start date: May 21, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label trial of disulfiram in combination with copper gluconate in patients with treatment-refractory multiple myeloma. The trial is designed to assess the Phase 2 Recommended Dose (RP2D) of disulfiram and copper gluconate in combination. The trial will open with dose escalation, followed to an expansion cohort to further characterize the safety and tolerance of the combination. Dose escalation will utilize a standard 3+3 design and will test up to five dose levels. Dose levels will be separated into two sequential parts defined by the fixed dose of copper as copper gluconate administered with ascending doses of disulfiram. Part 1 of dose escalation will consist of dose levels 0 and 1 with the option to reduce to Dose Level -1 if Dose Level 0 is deemed intolerable. Part 2 will test dose levels 2 and 3. The Dose Level deemed to be the RP2D will be used in dose expansion.

NCT ID: NCT04465760 Terminated - Lymphoma Clinical Trials

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Start date: February 25, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well xisomab 3G3 works in preventing catheter-associated blood clots (thrombosis) in patients with cancer receiving chemotherapy. Many patients with cancer develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Xisomab 3G3 is type of drug called a monoclonal antibody that may prevent blood clots caused by a catheter in patients receiving chemotherapy.